Imugene(ASX) IMU

Market CapA$21.41M

Since IPO (2002)-99%

5 YearN/A

1 Year-91%

1 Month-38%

A$0.04

-7.14%

-0.00Today

Imugene last closing stock price
Metric	Price	Date
Last close	AUD 0.04	2026-10-09

Imugene stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+5.41%	AUD 0.04	2026-10-02
1 month	-38.1%	AUD 0.06	2026-09-09
3 month	-62.86%	AUD 0.11	2026-07-10
Year to date	-89.32%	AUD 0.37	2025-12-31
1 year	-91.24%	AUD 0.45	2025-10-09
Since inception	-98.81%	AUD 3.29	2002-09-02

Imugene Financials at a Glance

Market Cap

A$21.41M

Revenue (TTM)

A$4.40M

Net Income (TTM)

-A$174.36M

EPS (TTM)

-A$0.32

P/E Ratio

-0.12

Dividend

A$0.00

Beta (Volatility)

0.17 (Low)

Dividend

A$0.00

Beta (Volatility)

0.17 (Low)

Price

A$0.04

Volume

1,833,594

Open

A$0.04

Price

A$0.04

Volume

1,833,594

Open

A$0.04

Previous Close

A$0.04

Daily Range

A$0.04 - A$0.04

52-Week Range

A$0.04 - A$0.43

Estimated Earnings Date

Mar 3, 2027

Dividend

A$0.00

Beta (Volatility)

0.17 (Low)

Price

A$0.04

Volume

1,833,594

Open

A$0.04

Previous Close

A$0.04

Daily Range

A$0.04 - A$0.04

52-Week Range

A$0.04 - A$0.43

Estimated Earnings Date

Mar 3, 2027

IMU News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Imugene

Imugene Limited is a clinical-stage immuno-oncology company focused on developing innovative immunotherapies to activate the immune system in cancer patients. The company is headquartered in Sydney, Australia, and is dedicated to eradicating tumors through its advanced therapeutic products.

Products and Services

Azer-cel: Allogeneic CAR T cell therapy in phase 1 trial for non-Hodgkin lymphoma
CF33 VAXINIA: Oncolytic virus therapy in phase 1 trial for advanced solid tumors
HER-VAXX: B-cell immunotherapy vaccine targeting metastatic gastric cancer, completed phase 2 trial

Growth Outlook

Strong pipeline with multiple products in various clinical trial phases
Recent advancements in HER-VAXX and PD1-Vaxx trials show promising results
Increased investor interest as the company progresses through clinical trials

Financial Highlights

Recent quarterly revenue of AUD 0, reflecting ongoing R&D investments
Trailing twelve months (TTM) net income of AUD -67.5 million, indicating significant R&D focus
Cash and cash equivalents of AUD 2.6 million as of June 2026, supporting ongoing operations

Imugene Limited is positioned in the biotechnology sector, focusing on groundbreaking therapies that leverage the body's immune system to combat cancer. The company's diverse product pipeline, including therapies in various stages of clinical trials, highlights its commitment to innovation in cancer treatment. Despite recent financial challenges, the ongoing development of its therapies and the potential for future breakthroughs may attract interest from investors looking for opportunities in the healthcare sector. The company's strategic focus on immuno-oncology aligns with the growing demand for effective cancer treatments, making it a noteworthy entity in the biotechnology landscape.

AI Generated • Sep 20, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

Leslie Chong

Website

imugene.com

Headquarters

Sydney, NSW 2000, AU

IMU Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-414.10%

Return on Capital

-489.63%

Return on Assets

-457.36%

Earnings Yield

-8.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$21.41M

Shares Outstanding

548.90M

Volume

1.83M

Avg. Volume

2.84M

Financials (TTM)

Gross Profit

-A$2.45M

Operating Income

-A$144.49M

EBITDA

-A$138.58M

Operating Cash Flow

-A$120.42M

Capital Expenditure

-A$7.55M

Free Cash Flow

-A$127.97M

Cash & ST Invst.

A$2.63M

Total Debt

A$6.30M

Imugene Performance Analysis

Imugene annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2023	2023-06-30	AUD 0	N/A
2024	2024-06-30	AUD 0	N/A
2025	2025-06-30	AUD 0	N/A
2026	2026-06-30	AUD 0	N/A

Imugene sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-31	140.6%
Q4	2025-06-30	149.5%
Q2	2025-12-31	-100.0%
Q4	2026-06-30	N/A

Imugene annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2023	2023-06-30	AUD -0.21	-10.1%
2024	2024-06-30	AUD -0.72	249.6%
2025	2025-06-30	AUD -0.22	-69.9%
2026	2026-06-30	AUD -0.32	49.4%

Imugene sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2024-12-31	42.1%
Q4	2025-06-30	57.2%
Q2	2025-12-31	-38.0%
Q4	2026-06-30	-46.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2026YOY CHG

Revenue

A$0.00

+100.0%

Gross Profit

-A$1.64M

+47.2%

Gross Margin

0.00%

N/A

Market Cap

A$21.41M

N/A

Market Cap/Employee

A$1.53M

N/A

Employees

N/A

Net Income

-A$67.52M

+16.6%

EBITDA

-A$31.48M

+55.9%

Quarterly Fundamentals

Name

Q4 2026YOY CHG

Total Cash

A$2.63M

-97.2%

Total Debt

A$6.30M

+307.2%

Accounts Receivable

A$2.38M

-81.2%

Inventory

A$4.41M

+298.2%

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$6.30M

+590.3%

Return on Assets

-4.57%

N/A

Return on Invested Capital

-8.16%

N/A

Free Cash Flow

-A$18.88M

+59.7%

Operating Cash Flow

-A$18.88M

+61.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PCK.AXPainChek Limited

PCK.AXPainChek LimitedA$0.10-1.04%

EZZ.AXEZZ Life Science Holdings Limited

EZZ.AXEZZ Life Science Holdings LimitedA$0.36+2.86%

RAD.AXRadiopharm Theranostics Limited

RAD.AXRadiopharm Theranostics LimitedA$0.01+0.00%

ALA.AXArovella Therapeutics Limited

ALA.AXArovella Therapeutics LimitedA$0.05+8.33%

ATH.AXAlterity Therapeutics Limited

ATH.AXAlterity Therapeutics LimitedA$0.36-2.74%

RCE.AXRecce Pharmaceuticals Ltd

RCE.AXRecce Pharmaceuticals LtdA$0.30+3.51%

BIO.AXBiome Australia Limited

BIO.AXBiome Australia LimitedA$0.41+1.25%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

TAT&T

TAT&T$22.18-9.81%

WFFWf

WFFWf$12.29+499.51%

VZVerizon Communications

VZVerizon Communications$41.65-8.75%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$162.57+1.25%

NVDANvidia

NVDANvidia$229.28-0.52%

VEEAVeea

VEEAVeea$5.70+47.29%

NUNu Holdings

NUNu Holdings$16.12+4.81%

Questions About IMU

What is the current price of Imugene?

Imugene is trading at A$0.04 per share.

What is the 52-week range for Imugene?

Over the past 52 weeks, Imugene has traded between A$0.04 and A$0.43.

How much debt does Imugene have?

As of the most recent reporting period, Imugene reported total debt of A$6.30M.

How much cash does Imugene have on hand?

Imugene reported A$2.63M in cash and cash equivalents in its most recent financial results.

What is Imugene’s dividend yield?

Imugene does not currently have a dividend yield.

Imugene(ASX) IMU

Imugene Financials at a Glance

IMU News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Imugene

IMU Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Imugene Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IMU

What is the current price of Imugene?

What is the 52-week range for Imugene?

How much debt does Imugene have?

How much cash does Imugene have on hand?

What is Imugene’s dividend yield?

Premium Investing Services